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Abstract
Cell death has a fundamental impact on the evolution of degenerative disorders, autoimmune processes,
inflammatory diseases, tumor formation and immune surveillance. Over the past couple of decades extensive studies
have uncovered novel cell death pathways, which are independent of apoptosis. Among these is necroptosis, a tightly
regulated, inflammatory form of cell death. Necroptosis contribute to the pathogenesis of many diseases and in this
review, we will focus exclusively on necroptosis in humans. Necroptosis is considered a backup mechanism of
apoptosis, but the in vivo appearance of necroptosis indicates that both caspase-mediated and caspase-independent
mechanisms control necroptosis. Necroptosis is regulated on multiple levels, from the transcription, to the stability and
posttranslational modifications of the necrosome components, to the availability of molecular interaction partners and
the localization of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), receptor-interacting serine/threonine-
protein kinase 3 (RIPK3) and mixed lineage kinase domain-like protein (MLKL). Accordingly, we classified the role of
more than seventy molecules in necroptotic signaling based on consistent in vitro or in vivo evidence to understand
the molecular background of necroptosis and to find opportunities where regulating the intensity and the modality of
cell death could be exploited in clinical interventions. Necroptosis specific inhibitors are under development, but >20
drugs, already used in the treatment of various diseases, have the potential to regulate necroptosis. By listing
necroptosis-modulated human diseases and cataloging the currently available drug-repertoire to modify necroptosis
intensity, we hope to kick-start approaches with immediate translational potential. We also indicate where necroptosis
regulating capacity should be considered in the current applications of these drugs.
Facts
● Necroptosis is closely associated with the
pathogenesis of many human diseases.
● The in vivo appearance of necroptosis indicates that
both caspase-independent and caspase-dependent
mechanisms control this cell death pathway.
● More than 70 human molecules play a role in the
regulation of necroptosis.
● More than 20 approved drugs have the potential to
regulate necroptosis.
Open Questions
● How can we monitor and regulate necroptosis in
human diseases?
● What are the main molecular targets in caspase
independent regulatory mechanisms of necroptosis?
● How effective can the off-label use of already
approved drugs in necroptosis-driven diseases be?
Introduction
The development and homeostasis of multicellular
organisms depends on the balance between cell pro-
liferation and cell death. In the past few years new regu-
lated cell death pathways have been discovered and
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Gábor Koncz (konczgb@gmail.com)
1Department of Immunology, Faculty of Medicine, University of Debrecen,
Debrecen, Hungary
2Doctoral School of Molecular Cellular and Immune Biology, University of
Debrecen, Debrecen, Hungary
Full list of author information is available at the end of the article
These authors contributed equally: Tamás Molnár, Anett Mázló
Edited by A. Oberst
Official journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
classified1. One of these tightly controlled inflammatory
cell death pathways – necroptosis – has come to the
center of attention because of its known contribution to
the pathogenesis of many diseases1,2.
Many death-, pattern recognition-, DNA binding-,
adhesion, and dependence-receptors, immune reactions,
pathogens and various drugs have been identified as
necroptosis triggers1,3. Necroptosis utilizes a signaling
pathway requiring the involvement of receptor interacting
protein kinase 3 (RIPK3)4, mixed lineage kinase domain-
like protein (MLKL)5 and upon stimulation of death
receptors (DR)2 RIPK1. RIPK3 oligomerization and its
subsequent phosphorylation allows the RIPK3-MLKL
interaction and the double phosphorylation of MLKL by
RIPK36. After this step, MLKL forms oligomers and
translocates to the plasma membrane to execute
necroptosis (Fig. 1). Generally, necroptosis requires inhi-
bition of caspases3,7 or the absence of the pro-caspase-8-
activating adaptor Fas-associated protein with death
domain (FADD)8, demonstrating the crucial role of the
apoptotic platform in the negative regulation of necrop-
tosis. Active caspases block necroptosis2 preferentially
through the cleavage of RIPK19, RIPK33,10, and cylin-
dromatosis (CYLD) protein11 which acts as the de-
ubiqutinase enzyme of RIPK1. During DR-mediated sig-
naling, inhibitors of apoptosis proteins (IAPs) initiate the
ubiquitination of RIPK1 and this process favors cell sur-
vival12. Blockage of IAPs or the subsequent events of IAP-
induced signaling strongly support necroptosis13. Various
molecular pathways have been documented as regulators
of downstream necroptotic events beside MLKL-
mediated membrane rupture, but the complexity of the
signaling and regulation network of necroptosis are still
not fully understood.
The immunological outcome of cell death can be clas-
sified as anti-inflammatory or pro-inflammatory and tol-
erogenic or immunogenic1. Dominance of apoptosis
ensures the tolerogenic outcome of cell death under
physiological conditions. When apoptosis signaling is
blocked, necroptotic pathways are activated and the dying
cells have the potential to initiate innate immune
responses via production of damage associated molecules
(DAMPs) resulting in an inflammatory response14. Sig-
naling in necroptotic cells also supports the cross priming
capacity of dendritic cells (DCs)15.
In this review our goal was to understand the molecular
background of necroptosis in humans and to find
potential points of clinical intervention. We summarized
how the expression, posttranslational modification, and
localization of necroptotic molecules are regulated and
what the interaction partners of the necrosome complex
are. Finally, we provide an overview of drugs, which are
already used in the clinic and have been shown to affect
necroptosis.
Necroptosis involved in human diseases
Currently, necroptosis is mainly documented in various
in vivo mice models16,17, but regulated necrosis con-
tributes to the pathogenesis of many human diseases
(Table 1). Both up and down-regulation of necroptosis
and misregulation of the apoptosis-necroptosis transition
which modifies the immunological outcome of cell death
contribute to the evolution of degenerative disorders,
autoimmune processes, inflammatory diseases or the
immune surveillance of tumors.
Some physiological processes such as alteration of glu-
cose level, oxygen deprivation or immune reactions
resulted in elevated RIPK3 expression allowing in vivo
emergence of necroptosis. Hyperglycemia (35–40mM
glucose) markedly enhanced the expression of RIPK3 in
various cell lines and primed cells for necroptosis18,19.
Similarly, upregulated expression of RIPK1, RIPK3 and
MLKL, and increased RIPK1/3 complex formation have
been observed in hypoxic cells20–22. At the same time
caspase-8 mRNA, functioning as a negative regulator of
necroptosis, was reported to be transiently decreased
following the deprivation of oxygen and glucose (OGD)23.
These processes are also involved in brain injury caused
by hypoxia-ischemia and OGD-induced necroptosis24,25.
Type I26–28 and type II27,29 interferons have been pub-
lished to induce increased expression of RIPK3, while
constitutive IFNβ signaling was demonstrated to increase
the intracellular level of MLKL28. CD8+T lymphocytes
can trigger both apoptosis and necroptosis, which make
these cells capable of killing tumor cells, even those that
Fig. 1 Backbone of necroptosis signaling. Various extra - or
intracellular signals activates the RIPK3 protein directly or through
RIPK1. RIPK3-mediated phosphorylation induces MLKL membrane
translocation and consequently, ion influx results in necroptosis147.
Survival signals through upregulation of IAPs or activation of TAK1
kinase pathway blocks RIPK1-induced signaling and protects cells
from unwanted necroptosis. Caspase-8-mediated cleavage of pro-
necroptotic RIPK1 and RIPK3 ensures the dominance of
immunologically silent apoptosis to immune stimulant necroptosis
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Table 1 Necroptosis related diseases in human
Disease Molecular changes in possible diagnosis
Lipid storage disorders
Niemann–Pick disease 224 * Increased expression of RIPK1 and RIPK3 in cerebellar tissue.
Skin disorders
Toxic epidermal necrolysis 58 * Upregulated RIPK3 expression and elevated MLKL phosphorylation in skin tissue sections
Cutaneous vasculitis50 Strong phospho-MLKL signals in infiltrating tissue neutrophils in biopsy specimens
Psoriasis50
Lichen Planus56 Detection of highly upregulated RIPK3 and increased phosphorylation of RIPK3 and MLKL
Systemic lupus erythematosus56
Cardiovascular diseases
Chronic Heart Failure38 * Elevated expression of RIPK1and RIPK3, increased RIPK3 and MLKL phosphorylation,
downregulation of active caspase-3 and 7
Coronary artery disease43 Patients with CAD plasma RIP3 levels were significantly higher than controls
Unstable atherosclerosis40 High RIPK3 and MLKL expression. Increased phosphorylation of MLKL.
Abdominal Aorta Aneurysm41,42 Elevated levels of RIPK1 and RIPK3 in AAA tissue
Neurodegenerative disorders
Multiple Sclerosis32 High RIPK1 and RIPK3 expression. Increased phosphorylation of RIPK1 and RIPK3. Reduced
expression of active Caspase-8.
Amyotrophic Lateral Sclerosis35,36 Elevated levels of RIPK1, RIPK3 and MLKL, increased RIPK1 and p-MLKL phosphorylation in both
microglia and oligodendrocytes primarily localized in the white matter.
Alzheimer’s disease33,34 Detection of activated RIPK1
Spinal cord injury37 After SCI, strong RIP3-, phosphorylated-MLKL- (pMLKL) and HMGB1-immunoreactivities were
detected.
Gastrointestinal diseases
Alcoholic liver disease17 Increased expression of RIPK3
Non alcoholic fatty liver disease44,45 Increased RIPK3 and MLKL expression
Drug-induced liver injury46 Elevated phosphorylation of MLKL
Crohn’s disease17 Increased expression of RIPK3
Primary biliary cholangitis47 Elevated expression of RIPK3, phosphorylation of MLKL, insoluble aggregates of RIPK1, RIPK3
and MLKL
Ulcerative colitit49,50 Strong phospho-MLKL signals in infiltrating tissue neutrophils in biopsy specimens
IBD in children48 Increased expression of RIPK3 and MLKL and reduced caspase-8 in patient’s tissue
Autoimmune diseases, Immunodeficiency
Immunodeficiency, arthritis and intestinal
inflammation62,63
Loss-of-function mutations in RIPK1 detected with exome sequencing
Renal diseases
Acute kidney injury51 Phosphorylation of RIPK3 and MLKL
Autosomal dominant polycystic kidney disease53 Phosphorylation of RIPK3 and MLKL
Kidney ischemia-reperfusion injury52 Phosphorylation of MLKL
Autoimmune vasculitis in the kidney54 Phosphorylation of MLKL in neutrophils
Skeletal system diseases
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escaped apoptosis30. T cell-mediated necroptotic cytolysis
also plays a role in activation induced cell death, and can
be critical in the development of autoimmune reactions31.
Upregulation of necroptosis in human diseases
Necroptosis takes part in the pathogenesis of human
neurodegenerative disorders, such as Multiple Sclerosis
(MS)32, Alzheimer’s disease (AD)33,34, and Amyotrophic
Lateral Sclerosis (ALS)35,36. Defects in the activation of
caspase-8 were demonstrated in the pathologic process of
MS. Additionally, activated forms of RIPK1, RIPK3 and
MLKL were detected in the cortical lesions of human MS
samples32. Activated RIPK1 as a marker of necroptosis
was also observed in human AD brains correlating posi-
tively with Braak stage and negatively with brain mass and
cognition33,34. In ALS samples, multiple biochemical
hallmarks of necroptosis including increased levels of
RIPK1, RIPK3 and MLKL and elevated pRIPK1 and
pMLKL were detected in both microglia and oligoden-
drocytes. Importantly, pMLKL was primarily localized in
the white matter, where demyelination was found35. In
spinal cord injury strong RIPK3 expression and MLKL
phosphorylation were detected37.
In certain cardiovascular diseases, such as chronic heart
failure (HF) cell loss and subsequent deterioration of
contractile function is associated with elevated expression
of RIPK1, RIPK3, and pRIPK3. On the other hand, the
expression of caspase-8 was downregulated suggesting
activation of necroptosis signaling. MLKL expression did
not differ among the control and HF groups; however,
pMLKL were present in all HF samples, which is in
contrast to the controls where this was almost undetect-
able38. A genetic variant in the RIP3 promoter region was
associated with increased RIPK3 transcription, which
contributed to the poor prognosis of HF patients39.
In humans with unstable carotid atherosclerosis,
expression of RIPK3 and MLKL was increased, while the
phosphorylation of MLKL was detected in advanced
atheromas40. In patients with abdominal aorta aneurysm,
the tissue showed elevated levels of RIPK1 and RIPK3
proteins41,42. In coronary artery disease higher plasma
RIPK3 levels were detected than in controls43.
Regarding gastrointestinal diseases, increased RIPK3
expression was detected in liver biopsies from patients
with alcoholic liver disease17, while both RIPK3 and
MLKL expression was increased in non-alcoholic fatty
liver diseases44,45, as well as elevated MLKL phosphor-
ylation in drug-induced liver injury46. High levels of
RIPK3 and MLKL phosphorylation were also detected in
the liver biopsies of patients with primary biliary cho-
langitis, in contrast with its low hepatic expression in
healthy controls47. Similarly, increased levels of RIPK3
were documented in the terminal ileum of patients with
Crohn’s disease17 and elevated RIPK3 and MLKL levels
were observed in inflamed tissues of inflammatory bowel
disease (IBD) and allergic colitis patients, whereas the
expression of caspase-8 in these tissues was reduced48.
The migration of human neutrophils to sites of inflam-
mation was found to activate the RIPK3-MLKL pathway: a
strong pMLKL signal was observed in infiltrating tissue
neutrophils in samples collected from patients with
cutaneous vasculitis, ulcerative colitis, and psoriasis49,50.
Phosphorylation of MLKL molecules was also detected
in human acute kidney injury biopsies51, in biopsies taken
immediately after excision for transplantation52 and in
autosomal dominant polycystic kidney disease53 repre-
senting involvement of necroptosis in renal disorders.
Antineutrophil cytoplasmic antibody (ANCA) induces
neutrophil extracellular traps via necroptosis and causes
subsequent endothelial cell damage. ANCA-associated
vasculitis exhibited a specific p-MLKL staining in glo-
merular neutrophils in human kidney biopsies54.
Concerning skin diseases, human biopsy samples
obtained from patients with Lichen Planus (LP) and Sys-
temic lupus erythematosus (SLE) confirm the role of
necroptosis in their development. RIPK3 and MLKL acti-
vation was demonstrated in podocytes in renal biopsies
from patients with lupus nephritis55. LP and SLE tissue
sections showed enhanced epidermal expression of phos-
phorylated RIPK356. B cells from SLE patients also sig-
nificantly displayed high expression levels of necroptosis-
related genes57. As we already mentioned, phosphorylation
of MLKL in the infiltrated human neutrophils was also
found in cutaneous vasculitis and psoriasis49,50.
Table 1 continued
Kashin‐Beck disease60 High RIPK3 expression and necrotic cell death morphology in the middle zones of KBD samples.
Negative staining for caspase‐3
Dental diseases
Chronic periodontitis61 Elevated levels of RIPK1, phosphorylated RIPK3, MLKL, phosphorylated MLKL and cFLIPL in
gingival tissues
Pulmonary diseases
Chronic obstructive pulmonary disease59 Increase in expression of RIPK3 and PINK1 using confocal imaging
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Upregulation of RIPK3, and elevated MLKL phosphor-
ylation were observed in the skin samples from patients
with toxic epidermal necrolysis in correlation with
unwanted necroptosis and subsequent inflammation58.
Expression of RIPK3 and dynamin-related protein 1
(Drp1) was increased in lung tissue homogenates col-
lected from patients suffering from chronic obstructive
pulmonary disease, proving the role of necroptotic cell
death in pulmonary diseases59. In Kashin–Beck disease
(KBD) necroptosis dominates as a cell death mechanism
in the middle zone of cartilage from KBD children60.
Necroptotic cell death is involved in the progression of
chronic periodontitis, as gingival tissue in patients showed
increased levels of RIPK1, RIPK3, and MLKL, as well as
increased phosphorylation of MLKL61.
Although RIPK1 is one of the key molecules required
for execution of necroptosis, patients with its complete
deficiency due to homozygous mutations suffered from
recurrent infections, early-onset of IBD and progressive
polyarthritis. In vitro, cells with RIPK1 deficiency showed
impaired mitogen-activated protein kinase activation and
cytokine secretion and were prone to necroptosis62,63.
Role of necroptosis in cancers
An increasing number of studies have been published
about the importance of necroptotic cell death in anti-
cancer therapies, which have been extensively reviewed in
recent papers64,65.
Briefly, both pro- and anti-tumoral effects have been
demonstrated following necroptosis in cancer develop-
ment and progression. The anti-tumoral effect of
necroptosis has been shown in many types of cancer in
which the expression of RIPK366,67 or MLKL68 was
silenced or polymorphisms in their coding genes lead to
modified expression of necrosomal components66,69. In
general, necroptosis resistance of cancer cells is a com-
mon process, and escape from necroptosis was suggested
to be a potential hallmark of cancer, similar to the escape
from apoptosis64. Additionally, effective anti-cancer
agents trigger immunogenic cell death, inducing the kill-
ing of the transformed cells and provoking the members
of innate and adaptive immune system to attack. Beside
the massive release of DAMPs, necroptotic cells create a
great possibility to trigger the activation of CD8+T cells
via cross presentation15,70. The dual ability of necroptosis
to activate innate and adaptive immunity simultaneously
makes this cell death pathway a promising therapeutic
target.
However, the tumor-promoting outcome of necroptosis
has also been shown. RIPK3 and MLKL expression seems
to vary among tissue samples from different subtypes and
stages of cancer, and downregulation of necroptosis
mediators has also been published in various cancers71–73.
Upregulated RIPK3 expression is a general phenomenon
in tumor necrotic areas playing a critical role in tumor
growth and metastasis74. Necroptosis-induced inflamma-
tion contributes to tumorigenesis and necroptosis can
also lead to an immunosuppressive tumor micro-
environment75. The immune-suppressing environment
was associated with necroptosis-induced expression of the
chemokine attractant CXCL171. It has also been shown
that tumor cells induce necroptosis of endothelial cells,
which promotes tumor cell extravasation and metas-
tasis76. Thus, we can conclude that necroptosis occurs in
different phases during tumorigenesis and plays an
ambivalent role in tumor formation.
Molecular mechanisms in the regulation of
necroptosis
To understand the molecular background of necropto-
sis and to find potential points of clinical intervention we
summarize below how the expression, the posttransla-
tional modification, and the localization of key necrop-
totic molecules (RIPK1, RIPK3 and MLKL) are regulated,
while also highlighting the interaction partners of the
necrosome complex.
Regulation the expression level of necroptotic proteins
RIPK3-RIPK3 homodimerization is sufficient to induce
necroptosis; after which, its kinase domain stimulates the
activation of RIPK3 through cis-autophosphorylation; a
prerequisite step for the recruitment of MLKL77–79. Thus,
RIPK3 dimerization is probably the most critical point of
necroptosis induction. Several lines of evidence support
the idea that increased expression of RIPK3 can induce its
oligomerization and can initiate necroptosis42,80. RIPK1
dimerization, and accordingly upregulation of RIPK1,
facilitates RIPK3 oligomerization, mainly upon death
receptor stimuli.
All aspects of necroptotic protein expression are inten-
sely regulated, including their transcriptional activity, the
stability of the expressed molecules and their degradation.
Specificity protein 1 (Sp1), a zinc-finger transcription
factor, directly regulates RIPK3 expression in cancer cells.
Knockdown of endogenous Sp1 significantly decreases the
transcription of RIPK3, while re-expression of Sp1 restores
necroptotic response in vitro81. Induction of necroptosis
by interferon gamma (IFN-γ) resulted in elevated levels of
RIPK327 and MLKL28,29,82. This effect was found to
depend on janus kinase 1 (JAK1) and its substrates: the
signal transducer and activator of transcription 1 (STAT1)
and interferon regulatory factor (IRF) transcription factors,
pinpointing interferon-stimulated gene factor 3 (ISGF3) as
a critical promoter83. Bromodomain-containing protein 4
(BRD4), a member of the bromodomain and extraterminal
domain (BET) family, has been shown to interact IRF1 and
to upregulate MLKL transcription84. Oncogenes such as
BRAF and AXL have also been implicated in the regulation
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of RIPK3 expression67. The activity of RIPK3 promoter is
tightly controlled by methylation67,85–87 (Fig. 2a).
Ubiquitin-like PHD and RING finger domain-containing
protein 1 (UHRF1) is essential for the maintenance of the
hypermethylation of the RIPK3 promoter and thus con-
tributes to the silencing of RIPK3 expression in quiescent
cells.
Following transcriptional regulation multiple processes
control the protein level of necrosome components. The
heat shock protein 90 (HSP90) and CDC37 co-chaperone
complex increases the stability of all RIPK188, RIPK389,
and MLKL90 proteins. Consequently, inhibitors of HSP90
facilitated the degradation of these necroptotic compo-
nents and potently blocked necroptosis91. Protein levels of
RIPK1 and RIPK3 also decreased in FK506-binding pro-
tein 12 (FKBP12) knockdown cells92.
On the contrary, cells treated with Hsp70 inhibitors
underwent cell death, because Hsp70 enhances the sta-
bility of necroptosis antagonists, the RIPK1 regulators:
cIAP1/2, x-linked inhibitor of apoptosis protein (XIAP),
and the cellular FLICE-like inhibitor protein (cFLIP)93.
The expression of necroptotic molecules are down-
regulated by cleavage and proteosomal degradation. The
most well-known inhibitor of necroptosis, caspase-8
cleaves both RIPK19, RIPK394, and the necroptosis pro-
moting deubiquitinase CYLD proteins11. In macrophages,
cathepsins were also reported to be capable of processing
RIPK1, which resulted in significant decrease in necrop-
totic cell death95.
Several ubiquitin-ligases mediate K48-linked poly-
ubiquitylation and the subsequent proteasome dependent
degradation of necroptotic molecules: RIPK1 is regulated
by A2096, carboxyl terminus of Hsp70-interacting protein
(CHIP; also known as STUB1)97, optineurin (Optn)35,
Triad3a98, RIPK3 by CHIP97, Optn35, E3 ubiquitin ligase
Pellino 1 (PELI1)99, and MLKL by Optn (Table 2)35.
Knock down of any of these K48 ubiquitin-ligases
increased the sensitivity of necroptosis in both in vitro
and in vivo studies. (Fig. 2b).
Posttranslational modifications in the regulation of
necroptosis
Accumulating evidence suggests that cell death path-
ways are finely tuned by posttranslational modifications,
such as ubiquitination and phosphorylation. Multiple
excellent recent reviews go into extensive detail about the
role of these processes in necroptosis100, therefore we
only provide a brief overview of these processes below.
These pathways are mentioned in the tables and figures of
this manuscript in the interest of providing a compre-
hensive visual guide to these processes as well (Fig. 2c).
The necrosome is formed due to the phosphorylation
driven assembly of RIPK1, RIPK3, and MLKL4,80,101.
However several phosphorylation steps have been
published to inhibit necroptosis, chief among them the
transforming growth factor beta-activated kinase 1
(TAK1) complex, which is the most important hub for
these necroptosis-dampening signals102,103. Various pro-
tein complexes are assembled along TNFR signaling;
namely the survival (complex I), the apoptotic (complex
IIa and IIb) and the necroptosis inducer (complex IIc)
complexes. Upon activation TNFR recruits TRADD,
RIPK1, TRAF2, TRAF5 proteins. The gathered E3 ubi-
quitin ligases, cIAP-1 and cIAP-2 molecules, and the
linear ubiquitin chain assembly complex LUBAC (con-
sisting of HOIP, HOIL-1L and Sharpin)104 poly-
ubiquitinates RIPK1, and modified RIPK1 can now act as
a scaffold for TAK1 and the IKK complex105 which
molecules in many ways block RIPK1-mediated cell death
pathways, and thus the formation of complex II:106–108
These mechanism are: (1) By inducing the activation of
NFκB and MAPK signaling pathways and thereby
increasing the transcription of several survival molecules
such as cIAP1/2109 and FLIP110 (2) by blocking the
binding of cell death related molecules to RIPK1111 and
(3) by phosphorylating RIPK1106,108.
Interaction partners of necrosome components
The activity of necrosome components are also mediated
by molecular interactions (Fig. 2d). Three molecules, aur-
ora kinase A (AURKA), PPM1b, and HSP90 have been
recently identified as binding partners of RIPK390,91,112,113
and/ or RIPK191,112 in resting cells. AURKA112 and
PPM1b113 act as local inhibitors against spontaneous
necroptosis, since their silencing induces necroptosis.
PPM1b as a phosphatase prevents RIPK3 autopho-
sphorylation in resting cells113. AURKA together with its
downstream target, Glycogen synthase kinase 3β (GSK3β)
regulates the formation of RIPK1-RIPK3 and RIPK3-MLKL
complexes112. Silencing or blocking of AURKA, or inhibi-
tors of GSK3β result in necroptosis without any other
stimuli. Phosphorylation of GSK3β at Ser9 suppresses
necroptosis through interfering with the formation of
RIPK3-MLKL complex, however the direct targets of
GSK3β still have not been identified. The third molecule
which associates with RIPK3 in resting cells, HSP90, is
required for proper activation of necroptosis. Formation of
the HSP90–CDC37 complex is necessary for
RIPK1–RIPK3 interaction, thus it mediates RIPK3 activa-
tion during necroptosis. Unsurprisingly HSP90 inhibitors
can block TNF-induced systemic inflammatory response
syndrome (SIRS) in rats91. Additionally, membrane teth-
ered mucins have been shown to interact with RIPK1 to
block necroptosis in human bronchial epithelial cells
in vitro114.
The nuclear retinoic acid receptor gamma (RARγ) is
released from the nucleus to initiate the formation of cell
death signaling complexes by mediating RIPK1
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dissociation from TNFR when cIAP activity is blocked. In
vitro silencing of RARγ inhibited necroptosis and in vivo
results also confirmed that RARγ was essential for TNF-
induced RIPK1-initiated apoptosis and necroptosis
(Table 2)115.
Although RIPK1 initiates RIPK3 activation during death
receptor driven necroptosis, it plays an ambivalent role in
the regulation of RIPK3 aggregation. Under special cir-
cumstances instead of activation, RIPK1 acts to suppress
the spontaneous activation of RIPK3 by TIR-domain-
containing adapter-inducing interferon-β (TRIF)116 or
DNA-dependent activator of IFN-regulatory factors (DAI;
also known as ZBP1)78,117. RIPK3 oligomerization is able to
seed a RHIM dependent oligomer and this process is both
sufficient and a necessary step in necroptosis. RHIM
domains of RIPK1 intrinsically inhibit RHIM-mediated
RIPK3 aggregation by competing with the RHIM domain
of TRIF or DAI; conversely death domain-driven RIPK1
oligomerization results in RIPK3 aggregation and necrop-
tosis. In vivo results also reveal a kinase-independent
function for RIPK1 in inhibiting necroptosis. Caspase-8/
RIPK1 double-knockout animals die shortly after birth,
however, additional ablation of RIPK3 to make caspase-8/
RIPK1/RIPK3 triple knockouts rescues the viability of these
animals117–120. These data undoubtedly prove the anti-
necroptotic activity of RIPK1 under special conditions78.
Fig. 2 Direct interacting partners of main necroptotic signaling molecules. Sp1 transcription factor increases RIPK3 expression. INFγ-mediated
up-regulation of RIPK3 and MKLK level depend on JAK1 kinase, and STAT1 and IRF transcription factors. BRD4 cooperating with IRF1 also increase
MLKL transcription. Hypermethylation of the RIPK3 promoter by UHRF1 results in silenced RIPK3 expression. The stability of all RIPK1, RIPK3 and MLKL
proteins are increased by HSP90 and CDC37 co-chaperone complex and by FKBP12. The level of both RIPK1 and RIPK3 are down-regulated by
caspase-8-mediated cleavage. Cathepsins are also capable of processing RIPK1. A20, CHIP, Optn, PELI1 and Triad3a ubiquitin-ligases mediate K48-
linked polyubiquitylation and the subsequent proteasome dependent degradation of: RIPK1, RIPK3 and/or MLKL Upon necroptosis human RIPK1 is
autophosphorylated at ser14, ser15, ser161, ser166 and RIPK3 at ser199 and ser227 and ser277. The transient phosphorylation of RIPK1 at ser321 is
phosphorylated transiently by TAK1 leads to RIPK1-independent apoptosis and the sustained phosphorylation of RIPK1 by TAK1 at ser321, ser332,
ser334 and ser336 induces RIPK1 kinase activation106. IKKα/IKKβ also phosphorylate RIPK1 at ser25 and thereby block RIPK1 activity108,214,215. Mitogen-
activated protein kinase-activated protein kinase 2 (MK2) mediates phosphorylation of RIPK1 at ser321 and ser336 and restrains integration of RIPK1
into the cytosolic death complex107,216,217. The phosphorylation at ser89 by a currently unknown kinase inhibits the RIPK1 kinase activity218.
Ubiquitylation of RIPK1 at Lys115 by PELI219 or Lys377 by cIAP1, cIAP2 and Parkin220 promotes necroptosis. LUBAC complex and the deubiquitinase
CYLD regulates M1 ubiquitination of RIPK1221. Lys363 ubiquitylation of RIPK3 leads to its proteasomal degradation. RIPK3 is responsible for the
phosphorylation of MLKL at thr357 and ser358. TAM (Tyro3, Axl, and Mer) family of receptor tyrosine kinases phosphorylate MLKL on Tyr376 to
facilitate MLKL oligomerization145. MLKL is also phosphorylated on Ser441 by a still unidentified kinase222. Caspase-8 mediates the cleavage and
inactivation of RIPK1 at asp324 and RIPK3 at asp328. O-GlcNAcylation of the RIPK3 at thr467 by OGT prevents necroptosis223. Red names indicate
interaction partners of RIPK1, RIPK3, MLKL which activate necroptosis, blue marks necroptosis inhibitors
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Table 2 Molecules in necroptotic signaling
Interaction
partners
Outcome of
silencing
Confirmed in KO mice Interactions with… Regulatory mechanism
RIPK1 RIPK3 MLKL
A20 ↑225,226 The embryonic lethality of A20 −/− mice is
inhibited by RIPK3 KO225,227. A20 protects
T cells from necroptosis225
+225 +225 A20 KO elevates RIPK3 K5 ubiquitination and
RIPK1-RIPK3 complexes formation225, but A20
replaces K63 polyubiquitin from RIPK1 with
K48 polyubiquitin, leading to RIPK1
degradation49.
ABIN-1 ↑67 The embryonic lethality of Abin-1−/− mice is
blocked by inhibition of RIPK1 or absence of
RIPK367.
ABIN-1 is an ubiquitin-binding protein
associated with TNFR and A20. Regulates the
RIPK1 ubiquitylation/deubiquitylation
mediated by LUBAC and pA2067.
ADAM9 ADAM10 ↓150 + 150 MLKL binds with multiple ADAMs to mediate
the shedding of cell-surface proteins.
ALIX and
syntenin-1
↑149 + 149 Phosphorylated MLKL was removed from
membranes through ALIX–syntenin-
1–mediated exocytosis149.
APC11 ↓228 + 228 APC11 promotes necroptosis induced by
TNF/5z-7/Zvad, but not upon TCZ.
Interaction with RIPK1 was detected upon
RIPK1- dependent apoptosis
Akt ½ mTOR ↓ 124,125 + 124 Akt/mTOR activation occurs downstream of
RIPK1–RIPK3, it does not affect RIPK1–RIPK3
complex assembly124,126
Atg5 ↓128 + 199 + 199 Atg5 needs to the formation of necrosome
membrane that aggregate RIPK1 and
RIPK3128.
AURKA ↑ 112 AURKA inhibitor stimulated MLKL
phosphorylation and inhibited the growth of
implanted tumors. AURKA and GSK3β are
Associated With Poor Prognosis in Human
Pancreatic Cancer112.
+ 112 + 112 -112 KO of AURKA enhanced RIPK1-RIPK3 and
RIPK3-MLKL interactions. Its kinase activity is
required for its anti-necroptotic effect. GSK3β
acts as a downstream target of AURKA in
necroptosis.
Bax/Bak ↓229,230 TNFα and zVAD treatment elevated MLKL in
the mitochondrial fraction229.
CypD-mediated regulated necrosis can be
responsible for Bax/Bak-regulated necrosis.
BRD4 ↓84 BRD4 contribute to the transcription
complex to regulate the expression of
MLKL84.
CAMKII ↓127 KO of CaMKII abrogated I/R-induced necrosis
and blocked doxorubicin-induced contractile
dysfunction, myocardial necrosis and
mortality127
+ 127,231
RIPK3-mediates activation of CaMKII,
including direct phosphorylation and indirect
ROS-mediated oxidation127.
Caspase-2 ↑232 Caspase-2 KO enhanced the phosphorylation
of RIPK1 and MLKL232.
Caspase-8 ↑2,233 Casp8 KO leads to embryonic lethality, but
Casp8 KO mice fully viable when bred on
RIPK3 KO7,234. or MLKL KO235.
+ 4,115 + 4,115 Caspase-8 cleaves RIPK1236, RIPK394 and
CYLD to block necroptosis11.
c-Cbl ↓228 + 228 c-Cbl promotes necroptosis induced by TNF/
5z-7/Zvad, but upon TCZ. Interaction with
RIPK1 was detected upon RIPK1- dependent
apoptosis
CDC37 ↓91 + 91 + 91 RIPK3 activation requires the activity of an
HSP90 and CDC37 cochaperone complex91
CHIP/ STUB1 ↑97 CHIP KO mice showed postnatal lethality
with intestinal defects, which is rescued by
crossing with RIPK3 KO mice97.
+ 97 + 97 RIPK3 and RIPK1 expression level is negatively
regulated by CHIP E3 ligase mediated
ubiquitylation97.
CypD ↓10,127,176,196,237,238 In vivo analysis in mice suggested the
distinctness of CypD-mediated MPT from
RIPK1/RIPK3-mediated necroptosis237.
.Probably, cyclophilin-D (CypD) and RIPK3
mediate two independent form of
programmed necrosis10,176,227
CYLD ↓11,239–242 Inhibition of CYLD catalytic activity in
epidermal keratinocytes could delay the
development of inflammatory skin lesions in
FADDE-KO mice241.
CYLD deubiquitylates RIPK1 (both M1- and
K63), facilitating the association of RIPK1 and
RIPK311,239,243. CYLD promotes the
dissociation of TRAF2 from MLKL121.
Daxx ↓244 + 244 + 244 RIPK3 phosphorylated Daxx at Ser-668
triggering the nuclear export of Daxx244.
Drp1 ↓131,132 debated
in132,135
.PGAM5S activates Drp1 by
dephosphorylation, Drp1 facilitates
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Table 2 continued
Interaction
partners
Outcome of
silencing
Confirmed in KO mice Interactions with… Regulatory mechanism
RIPK1 RIPK3 MLKL
mitochondrial fragmentation131. but in cell
type specific manner132,135
ESCRT-III
components
ESCRT-I
components
↑52,245 .ESCRT-III machinery (CHMP2A, CHMP4B,
VPS4B, IST1) controls the duration of plasma
membrane integrity, when MLKL activation is
limited or reversed52,245
FADD ↑233 .Fadd KO mice are fully viable when bred
RIPK3 KO246,247 or Mlkl KO
backgrounds235,248,249
+4,101,240,250 +
4,101,216
+251 FADD functions together with caspase-8 in
the repression of necroptotic signaling.
FKBP12 ↓92 FKBP12 is essential for TNFα-induced
systemic inflammatory response syndrome.
Protein levels of RIPK1 and RIPK3 decreased
significantly in FKBP12 knockdown cells
cFLIP ↑7,226 ↓ 252 cFLIP KO (as well as caspase-8 KO or FADD
KO) results in embryonic lethality, FLIP KO,
FADD KO, RIPK3 KO mice are viable7,247
+ 253 c-FLIPL: procaspase-8 heterodimers inhibit
RIPK1 and RIPK3247,254.
cFLIPS and cFLIPR simply block procaspase-8
activation252.
Flottilin1-2 ↑149 Flotillin-null mice were highly senstitive to
TZ-induced SIRS149
+ 149 Phosphorylated MLKL was removed from
membranes through flotillin-mediated
endocytosis149
Gγ10 ↓157 In complex with Gβ2 and Src regulates
intracellular trafficking of necrosomes157
GSK3b ↑112 AURKA and GSK3β are associated with poor
prognosis in human pancreatic cancer112.
Phosphorylation of GSK3β at Ser9 by AURKA
suppresses the formation of the RIPK3-MLKL
complex.
GLUD1 ↓77 + 77 Targets of RIPK3, contributing to TNF-
induced ROS. GLUL and GLUD1 play a role in
using glutamine as a supplementary
substrate for the TCA cycle.
GLUL ↓77 + 77
HACE1 0 Increased susceptibility of hace-1 Ko mice to
DSS-induced colitis depends on RIPK3255
HACE1 is required for RIPK1-dependent
apoptosis via TRAF2 ubiquitination. HACE1
KO leads to necroptosis dominance to
apoptosis255.
HSP70 ↑93 Hsp70 is sustaining the stability of
necroptosis inhibitors, cIAP1/2, XIAP, and
cFLIPS/L
93.
HSP90 ↓90,91,256 HSP 90 inhibitor delayed death in TNF-
α–induced SIRS in rats, but not in mice91
+ 91 + 90,91 + 90 Hsp90 regulates the stability of RIPK1, RIPK3
and MLKL88,90,174. and blocks the membrane
translocation of MLKL256.
HtrA2/Omi ↓257 Inhibitor of HtrA2, significantly alleviated
DSS-induced colitis258
+ 258 HtrA2 promoted RIPK1 degradation during
necroptosis258 and induced
monoubiquitination of its substrate UCH-L1
during TNF-induced necroptosis257
cIAP1cIAP2 ↑240,259 .RIPK1+ /− allowed XIAP and cIAP1 double
KO to survive past birth, and prolonged
cIAP2 and cIAP1 double KO survival13,260
+ 240,261 + 261 .cIAP1 and cIAP2 mediates RIPK1
ubiquitination, allowing the recruitment of
LUBAC262–264
XIAP ↑264,265 RIPK1+ /− allowed XIAP and cIAP1 double
KO to survive past birth13
XIAP controls RIPK3-dependent cell death
and IL-1β secretion in response to TNF264
Loss of XIAP results in aberrantly elevated
ubiquitylation of RIPK1 outside of TNFR
complex264.
IKKα
IKKβ
↑108 The lethality induced by TNF+ TPCA-1
results from both RIPK1 kinase-dependent
apoptosis and necroptosis108. RIPK3 is
activated in Ikkα/β‐deficient livers, but does
not control cholestasis214
IKKα and IKKβ in addition to their known
function in NF-κB activation-directly
phosphorylate RIPK1108,214
IKK/NEMO ↑266,267 .IEC-specific FADD KO combined with RIPK3
KO prevented colitis development in NEMO
IEC-KO mice268,269
+ 266 NEMO inhibits necroptosis by binding to
ubiquitinated RIPK1267, blocks the RIPK1-
caspase-8 interaction, activates NF-kB266.
IPMK
IPTK
IPPK
↓142,143 Phosphorylated inositol products dissociate
the auto-inhibitory region from MLKL. IP
kinases needs to MLKL oligomerization and
membrane localization142.
IFNAR1 ↓83 IFNAR1-deficiency protects against LPS/zVad
induced septic shock83.
IFNAR1-deficient macrophages displayed
greatly reduced IRF9 transcript levels83.
IRF1 ↓270 IRF1 contributes to IFNγ-dependent and also
IFNγ-independent necroptosis270.
IRF9 ↓83
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Table 2 continued
Interaction
partners
Outcome of
silencing
Confirmed in KO mice Interactions with… Regulatory mechanism
RIPK1 RIPK3 MLKL
IRF9 KO macrophages were highly resistant
to necroptosis83.
JAK1
Stat1
↓27,271 RIPK1-RIPK3 complex requires JAK1/ STAT
dependent transcription27.
LRRK2 ↓228 + 228 LRRK2 promotes necroptosis induced by
TNF/5z-7/Zvad, but upon TCZ. Interaction
with RIPK1 was detected upon RIPK1-
dependent apoptosis228.
Lubac complex
(HOIP, HOIL1,
sharpin)
↑104,226,265 Absence of HOIP HOIL or Sharpin results in
RIPK1-kinase activity-dependent apoptosis
and necroptosis in various tissues. Co-
deletion of caspase-8 with RIPK3 or MLKL
prevents these phenotypes as well as RIPK1
kinase-dead knockin104,260,272–275
+ 265 + 221 HOIP and HOIL1 mediate ubiquitination of
RIPK1265. The generated linear ubiquitin-
chain and LUBAC recruits TAK1 complexes
and NEMO to the receptor complex243,276
MKRN1 ↑277 MKRN1 depletion facilitates necrosome
formation independently of FADD277.
MK2 ↑107,216 MK2 inactivation greatly sensitizes mice to
TNF-induced lethal shock216.
+ 216,217 + 217 Phosphorylation of RIPK1 on S321 or Ser336
by MK2 limits RIPK1 activation216, RIPK1
autophosphorylation and the RIPK1-FADD-
caspase-8 interaction107,217
MUC1 ↑114 + 114 MUC1 interacts with RIPK1 and inhibits
necroptosis by modulating the
phosphorylation of RIPK1 at Ser166114.
OGT ↑223 CLP induced lethal sepsis in the absence of
Ogt in macrophages, RIPK3 deficiency rescued
it223.
+ 223 RIPK3 O-GlcNAcylation on T467
downregulates necroptosis, blocks RHIM-
mediated protein interaction through steric
hinderance223
OPTN ↑35 Optn KO oligodendrocytes were sensitized
to TNFα-induced necroptosis. Optn double
KO with RIPK1D138N/D138N or with RIPK3 were
resistant35.
+ 35 RIPK1 K48 ubiquitination and degradation
was slower in Optn KO MEFs. Expression
levels of RIPK1, RIPK3 and MLKL, were all
increased in Optn KO mice35.
Otulin ↑278 OtulinC129A/C129A mice cause embryonic
lethality, it was prevented by triple KO of
caspase-8 and RIPK3278.
The main role of OTULIN is to maintain
LUBAC function by suppressing its auto-
ubiquitination278.
Parkin ↓279 + 220 Parkin is an E3 ubiquitin ligase involved the
K63 ubiquitination of RIPK1 to promote the
activation of NF-κB and MAPKs220, but parkin
knockdown protected cells from zVAD-
induced necroptosis279.
Parp1 ↓130 debated
in280,281
+ 130 .Parp1 is an effector downstream of RIPK1/
RIPK3130,281.
Debated in: Parp1 activation is rather a
consequence of necroptosis128,129
PDC ↓134 + 134 RIPK3 activates PDC by phosphorylating
PDC-E3. The activation of PDC increases
aerobic respiration, which generates ROS134.
PELI1 ↓↑99 In toxic epidermal necrolysis the expression
level of PELI1 decreases99.
+ 99,219 + 99 .PELI1 ubiquitinates RIPK1 (K115) promoting
necroptosis, but K363 ubiquitylation of RIPK3
leads to its degradation in proteasome99,219
PGAM5 ↓131 debated
in132,135
+ 131 + 131 .Upon necrosis induction, PGAM5S activates
Drp1 by dephosphorylation (S637) causing
mitochondrial fragmentation131., but it is cell
type specific132,135
PIPs ↓138 .PIPs as critical binders of MLKL are required
for plasma membrane targeting and
permeabilization in necroptosis138,139
PITPα ↓144 + 144 PITPα facilitates MLKL oligomerization and
plasma membrane translocation.
PKR ↓27,83 + 27 .IFNs transcriptionally activate PKR, which
then interacts with and phosphorylates RIPK1
to initiate necroptosis27,83
PPM1b ↑113 Ppm1b protects mice from TNF-induced SIRS
through dephosphorylating RIPK3113.
+ 113 Ppm1b prevents RIPK3 autophosphorylation
in resting cells113.
PYGL ↓77 + 77 Target of RIPK3, contributing to TNF-induced
ROS. PYGL regulates pyruvate production.
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MLKL association with RIPK3 is also suppressed by a
constitutive interaction of MLKL with a competitive
inhibitor, TRAF2, in resting cells. TRAF2 deubiquitina-
tion by CYLD promotes the dissociation of TRAF2 from
MLKL and allows necroptosis121. Two other molecules
inhibit cell death by blocking MLKL association with pro-
necroptotic components: Repulsive guidance molecule b
(RGMb) inhibits MLKL membrane translocation or
Table 2 continued
Interaction
partners
Outcome of
silencing
Confirmed in KO mice Interactions with… Regulatory mechanism
RIPK1 RIPK3 MLKL
RARγ ↓115 RARγ KO mice are protected from TNF+ Z-
vad induced death115.
+ 115 RARγ facilitates RIPK1 dissociation from TNF
receptor and the formation of death
signaling complexes115
RelA ↑282 Embryonic lethality of RelA KO mice is
partially prevented by the KO of RIPK3 or
MLKL, and it is fully rescued by the combined
ablation of Fadd and RIPK3 or MLKL or
RIPK1K459A282.
RelA KO leads to TNF-induced activation of
FADD-dependent apoptosis and RIPK3-
dependent necroptosis.
RGMb ↑122 Renal tubule-specific RGMB knockout mice
exhibited severe tubular injury, after renal
ischemia/reperfusion122
RGMb inhibits MLKL membrane translocation
or membrane binding122.
RIPK1 ↓↑78,118 .Caspase-8/RIPK1 double-knockout animals
die shortly after birth, ablation of RIPK3 to
triple knockouts, rescues the viability of these
animals. Deficiency in either RIPK3 or MLKL
prevented the development of skin lesions in
RIPK1E-KO mice117–120
+ 4 + 283 In a kinase-independent function of RIPK1
the RHIM domains of RIPK1 competes with
RHIM domain of TRIF or DAI to RHIM-
mediated RIPK3 aggregation, but RIPK1
oligomerization is initiative of death domain
driven necroptosis78.
Sp1 ↓81 Sp1 specifically binds to RIPK3 promoter and
regulates transcription81.
SPATA2 ↓284,285 In contrary to the in vitro data Spata2
deficiency sensitizes mice to SIRS induced by
TNFα221.
.SPATA2 binds CYLD into the TNF-RSC and to
HOIP. SPATA2 KO reduces phosphorylation
of RIPK1 and MLKL in TNF‐α‐induced
necroptosis284,285
Src ↓157 Interacting with Gγ10-Gβ2 complex regulates
intracellular trafficking of necrosomes157
STAT1 ↓27,83,271 IFN-γ failed to induce Mlkl transcription in
Stat1–/– mice29
.RIPK1, RIPK3 and MLKL requires JAK1/STAT1-
dependent transcription27,235
TAB1/2 ↑286 + 259 .TAB1/2 function to maintain TAK1 activity,
which is required for the survival of naive
macrophages286,287
TAK1 ↑102,103 Various tissue injuries have been published in
the absence of Tak1, These symptoms are
associated primarily with apoptosis and were
not rescued by RIPK3 deletion288.
+ 102,103,259 TAK1 inhibition triggered the degradation of
cIAP2, FLIP, and NFκB-p65. TAK1 blocks
RIPK1-RIPK3-FADD complex formation102,111.
Intermediate domain of RIPK1 is
phosphorylated transiently by TAK1106,289.
Downstream targets of TAK1 phosphorylates
RIPK1 (see, MK2, IKK, RelA)
TAM kinases ↓145 Tyro3,Axl,Mertk tripla KO mice were
completely resistant to the TZ-induced
SIRS145.
+ 145 TAM (Tyro3, Axl, and Mer) receptor tyrosine
kinases phosphorylate MLKL to protmote
MLKL oligomerizatin and necroptosis145
TRAF2 ↑121,290 TRAF2 deletion causes morbidity, RIPK3 KO
delays TRAF2 KO mortality121,291 and
suppressing TRAF2 augments ischemic brain
damage through necroptosis mechanism292
+ 121 TRAF2-MLKL association suppresses the
interaction of MLKL with RIPK3121.
Triad3a ↑98 Triad3a induces K48 ubiquitination and the
degradation of RIPK1, FADD and Caspase-898.
TRIF ↓83,116 Mice without functional TRIF did not show
macrophage loss and elevation of
inflammatory cytokines upon LPS/zVad293.
+ 294
+ 116,294
Activates necroptosis through RHIM
dependent association of TRIF with RIPK3
kinase116.
TRPM7 ↓146 + 146 + 146 TRPM7 is a target of MLKL for the induction
of Ca (2+ ) influx146.
TRX1 ↑123 + 123 TRX1 blocks necroptosis by maintaining MLKL
in a reduced inactive state123.
UCH-L1 ↓128,257 HtrA2/Omi induces monoubiquitination of
UCH-L1257
UHRF1 ↑81 UHRF1 silences RIPK3 expression via
promoter hypermethylation. Sp1 initiates
RIPK3 transcription in the absence of
UHRF181.
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membrane binding122 and Redox regulator thioredoxin-1
(TRX1) blocks MLKL disulfide bond formation, and
through it the critical polymerization of MLKL123.
Various molecules have been published to act as
downstream targets of RIPK3 and others to regulate
MLKL localization and/or activation. RIPK3 constitutes
an important upstream kinase of death associated protein
(Daxx), triggering its nuclear export. The Akt/mTOR
pathway124–126, and Ca2+/calmodulin-dependent protein
kinase II (CaMKII)127 are also active effectors of down-
stream necroptotic signaling. Accordingly, several models
suggest that effects on these signaling routes modify
necroptotic intensity. Poly [ADP-ribose] polymerase 1
(PARP-1)128 (debated in ref. 129,130) and phosphoglycerate
mutase family member 5 (PGAM5)131 (debated in ref. 132)
have been documented as cell type specific regulators of
downstream necroptotic events (Table 2).
Glucose metabolism and ROS production in necroptosis
Reactive oxygen species (ROS) have long been con-
sidered to contribute to necroptosis49,133–135. Oxidation of
specific cysteine residues in RIPK1 by ROS activates
RIPK1 autophosphorylation. A positive feedback loop is
generated because silencing of RIPK1 or RIPK3 reduces
ROS production. RIPK1 autophosphorylation is also
promoted by mitochondrial ROS and is essential for
RIPK3 recruitment into the necrosome. However,
necroptosis could occur without ROS induction in some
cell lines135,136.
Metabolic enzymes − human liver glycogen phosphor-
ylase (PYGL), glutamate-ammonia ligase (GLUL), gluta-
mate dehydrogenase 1 (GLUD1) − increase pyruvate
production from glycogen or play a role in glutamine
catabolism. These enzymes are activated by RIPK3,
resulting in enhancement of aerobic respiration and thus
likely contribute to TNF-induced ROS production80.
Pyruvate dehydrogenase complex (PDC) converts pyr-
uvate to acetyl-CoA, and triggers the entrance of meta-
bolic flux into the tricarboxylic acid cycle. Activated
RIPK3 in the necrosome enhances PDC activity by
phosphorylating the PDC E3 at T135 and plays a major
role in increasing aerobic respiration. Based on in vitro
studies, activation of these enzymes has additive effects to
aerobic respiration and ROS production (Table 2)80,134.
Intracellular localization of necrosome components
The intracellular localization of necrosome components
seems to be crucial in the regulation of necroptosis. The
RHIM domain of RIPK1 and RIPK3 mediates the
assembly of heterodimeric filamentous structures, and the
amyloid-like aggregation of RIPK1/RIPK3 complexes79.
Compromised cluster formation correlated with
decreased programmed necrosis. MLKL has also been
reported to form SDS-resistant, disulfide bond-dependent
polymers during necroptosis and it has been shown that
these MLKL polymers were independent of RIPK1/RIPK3
fibers137.
MLKL translocation to the cell membrane is an obli-
gatory step in necroptotic signaling. Phosphatidyl-inositol
phosphates (PIPs) as critical binders of MLKL are
required for plasma membrane targeting of MLKL and
subsequent membrane permeabilization in necropto-
sis138,139. Highly phosphorylated inositol products, but
not weakly phosphorylated precursors are able to displace
the MLKL auto-inhibitory brace region, which is a
necessary event for late plasma membrane breakdown and
cell death140,141. Accordingly, necroptosis requires inosi-
tol polyphosphate-specific kinase activity and in cells
containing mutant IP kinases, MLKL failed to oligomerize
and localize to membranes despite proper RIPK3-
dependent phosphorylation142. Deletion of inositol poly-
phosphate multikinase (IPMK), inositol-tetrakisphosphate
1-kinase (ITPK1)142 or inositol pentakisphosphate 2-
kinase (IPPK)143 inhibited necroptosis. Connected to
this, phosphatidylinositol transfer protein alpha (PITPα)
interacts with MLKL which facilitates MLKL oligomer-
ization and plasma membrane translocation144. Following
membrane localization TAM (Tyro3, Axl, and Mer)
family of receptor tyrosine kinases phosphorylate MLKL
to protmote MLKL oligomerizatin and necroptosis145.
Beside their direct pore forming ability, membrane-
localized MLKL regulates transient receptor potential
cation channel, subfamily M, member 7 (TRPM7), a non-
voltage-sensitive ion channel, for the mediation of Ca2+
influx146,147.
Once MLKL is membrane associated, all the endosomal
sorting complexes required for transport III machinery
(ESCRT-III), flotillin-mediated endocytosis and ALIX-
syntenin-1-mediated exocytosis act to sustain survival of
the cell. The ESCRT-III-driven plasma membrane repair
machinery limits the duration of the loss of plasma
membrane integrity upon MLKL activation52,148, while
endo- and exocytosis removes phospho-MLKL from the
plasma mebrane149. MLKL also forms a complex with
multiple membrane metalloproteinases upon necroptotic
stimulus. A disintegrin and metalloproteinase (ADAM)-
enzymes are activated to mediate the shedding of cell-
surface proteins in response to necroptotic stimuli and
through this process also play a key role in promoting
necroptosis, but only in adherent cells (Table 2)150.
RIPK1151, RIPK3152,153, and MLKL154,155 have all been
reported to localize to the nucleus and these transloca-
tions preceded necroptotic death154. RIPK3 and MLKL
have been shown to became activated in the nucleus, and
after their cooperative nuclear export, they contribute to
cytosolic necrosome formation155. Following the interac-
tion of RIPK3 and MLKL, the translocation of this com-
plex to mitochondria-associated membranes has also been
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demonstrated and this relocation was found to be essen-
tial for necroptosis signaling156. The intracellular traf-
ficking of necrosomes is regulated by the TNF-induced
guanine nucleotide-binding protein γ 10 (Gγ10) – Src
signaling pathway157, however, RIPK1/RIPK3 kinase
activity has no direct interaction with Gγ10 or on Src
kinase.
Drugs to regulate necroptosis intensity
In vitro studies prefer to use caspase inhibitors to
activate necroptosis, however we still do not fully
understand how necroptosis is activated under physiolo-
gical conditions. The in vivo appearance of necroptosis
indicates that in addition to caspase-mediated processes
various caspase independent regulatory mechanisms
control necroptosis. Drugs affecting either the expression
or the activity of necroptosis mediators, or that modify the
indirect regulators of necroptosis may have therapeutic
potential (Tables 3 and 4).
Regulation the expression level of necrosome components
Drugs that control the promoters of RIPK3 or MLKL or
modify the stability and degradation of these molecules
can regulate necroptosis sensitivity. Interferons27,29,
hypomethylating agents such as decitabine (5-aza-2′-
deoxycytidine) and 5-azacytidine (used in Myelodysplastic
syndromes and AML)87, histone deacetylase inhibitor
valproic acid158 (VPA), anti-fungal miconazole159, tradi-
tional Chinese medicine drugs (shikonin160,161, resibufo-
genin162, bufalin163, youdujing164, emodin165), and
components found in different plants (matrine166, geni-
pine167, lycorine168, quercetin169, curcumol170, Bulnesia
sarmientoi171) were all found to upregulate the expression
of RIPK1 or RIPK3.
On the other hand, various inhibitors of the HSP90 have
been documented to downregulate necroptosis (Kongen-
sin A172, G-TPP173, geldanamycin174, gamitrinib10,
DHQ3175 and 17-demethoxy-reblastatin175). Cyclosporine
A176, Diacerein177 (Used in Europe and Asia to treat joint
diseases), immunosuppressive and antiproliferative
Rapamycin178 and traditional Chinese medicine such as
patchouli alcohol179 have been also documented to reduce
the expression of principal necroptotic mediators. Ex-
527180 (which completed a phase II clinical trial in Hun-
tington disease) regulates necroptosis through the inhi-
bition of Sirt1 deacetylase.
Regulation the activity of necrosome components
Beside the expression of necrosome components, the
activity of these enzymes is also modified by various
drugs. Promising specific inhibitors are currently being
developed for the central molecules of necroptosis.
RIPK1, RIPK3, and MLKL (reviewed in refs. 181,182) which
may interfere with unwanted cell death and subsequent
inflammation. Multiple second mitochondria-derived
activator of caspase (SMAC) mimetics and TAK-1
(reviewed in ref. 183,184) inhibitors are being tested in
clinical trials to activate necroptosis for therapeutical
intervention, by restoring the sensitivity of apoptosis-
resistant tumors to cell death. Since these drugs are
reviewed elsewhere, we focus on currently available
necroptosis regulators.
Drugs currently used for the treatment of different
forms of tumors display anti-necroptotic activity (Dabra-
fenib185,186, Sorafenib187,188, Pazopanib189, Ponatinib189,
and Carfilzomib190) as does the anti-epilepsy drug Phen-
hydan191. Phenytoin51 (a clinically used anti-convulsant)
or herbal components such us wogonin192 and aucubin193
inhibit RIPK1 activity. All these drugs provide immediate
translational potential to dampen necroptosis-driven tis-
sue degradation. Presumably, these drugs will be additive
to the above-mentioned necroptosis inhibitors which
downregulate the expression of necrosome components.
On the other hand, radiation194, or chemotherapeutic
agents such as anthracyclines and oxaliplatin195, cispla-
tin196,197, 5-fluorouracil198 or the pan-BCL-2 inhibitor
Obatoclax199 (several phase two trials have been com-
pleted), traditional Chinese medicines such as resibufo-
genin162 (also tested in phase II of a clinical trial on
pancreatic cancer), aucubin193, tanshinone200 or neoal-
baconol201 have been documented to upregulate necrop-
tosis. Based on current results, these drugs regulate the
activity, and not the expression of necroptotic compo-
nent. As a mono-therapy these group of necroptosis
regulators could be ineffective in tumors that down-
regulate the level of RIPK3 or MLKL, but these medicines
may increase the effect of the above listed mediators in
combination therapy following the restoration of RIPK1
or RIPK3 expression in cancer cells.
Regulation the signaling of necroptotic pathway
Some drugs regulate necroptosis by modulating the
level or activity of partner molecules of the necrosome.
For example, VPA induces the release of SMAC from
mitochondria thereby upregulating necroptosis similarly
to the widely tested SMAC mimetics. Dimethyl fumarate
(DMF202, which is currently used in relapsing-remitting
multiple sclerosis) induces necroptosis via down-
regulation of the negative regulators of necroptosis such
as IAPs and cFLIPs. Aurora kinase inhibitors have been
shown to directly induce necroptosis and stimulated
intra-tumoral phosphorylation of MLKL203. Drugs
antagonizing Trx1function as necroptosis inducers. PX-
12123 (completed phase I of a clinical trial on advanced
metastatic cancer) and DMF204 target TRX1 and have
been shown to sensitize tumor cells to necroptosis.
Various drugs activate necroptosis via regulation of
downstream components of necroptosis. Adiponectin
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Table 3 Available drugs to modify necroptosis intensity
Drug/Agent Effect on
necroptosis
Mechanism Cells tested in necroptosis Application/clinical trial in general
Anthracycline
mitoxantrone195
↑ Induces MLKL phosphorylation Inhibits TC1 and EL4 cell lines-
induced tumor growth in vivo
in mice
Used in chemotherapy in for various cancer
Bortezomib/PS-
341207
↓ Disrupts the formation of RIPK1-
RIPK3 complex through stabilizing
of cIAPs
In vitro studies on primary bone
marrow- derived macrophages
Bortezomib (PS-341) is used in Multiple Myeloma
treatment
Carfilzomib190 ↓ Inhibits induction of pRIPK3
and pMLKL.
HT-29 cells Approved on Multiple Myeloma
Cisplatin196,197 ↑ Induces necrosome formation In vitro in various cell lines144,196
and in vivo in rats197.
Used in the treatment of numerous human
cancers295,296
Cyclosporine A176 ↓ Reduction in necroptosis markers
RIPK1 and RIPK3
In vivo rats cerebral ischemia-
reperfusion injury.
Widely used immunosuppressive drug
Dabrafenib185,186 ↓ RIPK3 inhibition by competing
with ATP binding
In vitro in normal human
hepatocytes and in vivo in mouse
models of ischemic injury.
Approved in BRAF-mutant melanoma
Dasatinib297 ↑ Plays a role in HMGB1-induced
necroptosis.
CCC-HEH-2 human embryonic
cardiac tissue derived cell lines
Used as an anticancer drug in CML patients
Dexmedetomidine211 ↓ Inhibition of HMGB1 expression H9C2 embryonic rat heart-
derived cells
Used in the intensive care setting for light to
moderate sedation
Diacerein177 ↓ Decreased renal expression of
RIPK3 and MLKL
Prevents necroptosis in acute
kidney injury in rats
Registered in some European Union and Asian
countries to treat joint diseases
Dimethyl
Fumarate202,204
↑ Depletion of GSH, increases MAPK
and ROS activation, inhibits the
Trx1/NFκB axis
Gastrointestinal CT26 and
lymphoid cancer cell lines Se-Ax,
HH and CEM cells
Used in relapsing-remitting Multiple Sclerosis
Fluorouracil198 ↑ Reduces cIAP1 protein level,
stabilizes binding between RIP1
and RIP3
In vivo xenograft experiments
with HT29 cells blocked
tumor growth
Used in chemotherapy in for various cancer
Hypomethylating
agents (decitabine, 5-
azacytidine and
RG108)87
↑ Restores RIPK3 in cancer cells
where RIPK3 had previously been
silenced.
Human breast tumor and AML
samples
Decitabine and Azacytidine are used in
Myelodysplastic syndrome and AML
Interferons, Type I-
II27,29,83
↑ Increases expression of RIPK3 and/
or MLKL
In vivo mice studies in
septic model
Used in differnt diseases
lithium126 ↑ Induces AKT- and mTOR-mediated
necroptosis
in vitro RT4 cells and human
primary schwannoma cells
Lithium is used as the first line treatment in bipolar
disorders
Melatonin212 ↓ Represses the RIPK3-PGAM5-CypD-
mPTP pathway
In vivo mice studies in cardiac
ischemia-reperfusion
Used for Jet Lag sleep disorder
Miconazole ↑ Upregulates RIPK3 and MLKL MDA-MB-231 cells Anti-fungal medication
oxaliplatin195 ↑ Induces ATP release in RIPK3 and
MLKL expressing cells
Inhibits TC1 and EL4 cell lines-
induced tumor growth in vivo
in mice
Used in clorectal cancer
Phenhydan 191 ↓ Suppresses phosphorylation and
activation of RIPK1, RIPK3
and MLKL.
in vitro MEFs, L929, NIH3T3, HT-29,
U937, and Jurkat mouse and
human cell lines
Used as an anti-convulsive drug
Phenytoin51 ↓ Partial inhibition of RIPK1 HT29 cells and RAW 264 cells,
human colon cancer cell lines
Used as anti-arrhythmic class Ib and as
anticonvulsant
Pazopanib189 ↓ Inhibits RIPK1 FADD-deficient Jurkat cells Approved for renal cell carcinoma and soft tissue
sarcoma
Ponatinib189 ↓ Inhibits both RIPK1 and RIPK3 FADD-deficient Jurkat cells Approved in some chronic myeloid leukemia and
some acute lymphoblastic leukemia
Rapamycin178 ↓ Inhibits RIP-1 expression Experimental retinal detachment
in rats
Approved for Prevention of transplant rejection in
Lymphangioleiomyomatosis, and to prevent
restenosis in coronary arteries following balloon
angioplasty
SAHA/Vorinostat208 ↓ HDAC inhibitor, activates NFkB and
p38 MAPK; inactivates JNK and Akt
kinase; enhances cFLIPL expression
In vitro L929 cells and human
neuroblastoma SH-SY5Y cells
Approved for the treatment of Cutaneous T cell
lymphoma
Sorafenib187,188 ↓ Reduces interaction of RIPK1 with
RIPK3, inhibits kinase activity of
RIPK1 and RIPK3
In vitro various cells and in vivo
protects against TNF-induced SIRS
and renal ischemia-
reperfusion injury
Approved for advanced thyroid and renal cell
cancer, hepatocellular carcinoma
Valproic acid158 ↑ Histone deacetylase inhibitor,
induces JNK1 activation and RIPK1
expression
In vitro rat PC12 cells Used in epilepsy and mood disorders298
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receptor agonists205 (tested in various clinical trials),
DMF202, neoablaconol206 induce ROS production.
Lithium126 (clinically used for treating bipolar disorders)
facilitates AKT-mTOR-mediated necroptosis, while
dasatinib (used drug in CML) induces HMGB1-mediated
necroptosis.
Necroptosis can be inactivated via the regulation of
interacting partners of the necrosome or by downstream
Table 4 Components of traditional medicine as necroptosis regulators
Drug/Agent Effect on
necroptosis
Mechanism Cells tested in necroptosis Application/ clinical trial in general
Aucubin193 ↓ Inhibits MLKL and RIPK1 activation lithium-pilocarpine induced epilepsy
rat model in vivo
Component of Eucommia ulmoides
Oliv., a traditional Chinese medicine
Bufalin163 ↑ Increases the expression of RIPK1
and RIPK3
MCF-7 and MDA-MB-231 human
breast cancer cells and in a mouse
xenograft model of human
breast cancer
Bufalin is a component of Chinese
medicine. Completed phase II of a
clinical trial on pancreatic cancer.
Bulnesia
sarmientoi171
↑ Induction of RIPK1 Human lung carcinoma cell lines A-
549, and H661, normal human lung
fibroblast MRC-5
Analgesic, wound-healing and anti-
inflammatory medicinal plant
Curcumol170 ↑ Upregulates the expression of RIPK1
and RIPK3
Human HSC-LX2 cells Extracted from the roots of the herb
Rhizoma Curcumae
Emodin165 ↑ Emodin upregulated the levels of
TNF-α, RIP1, RIPK3 and MLKL
Inhibits U-251 glioblastoma cell line
proliferation
Compound extracted from traditional
Chinese medicines
Genipin167 ↓ Attenuation of increased levels of
RIPK3, RIPK1/RIPK3 complexes and p-
MLKL
in vivo acute liver failure model
in mice
Major active compound of the
gardenia fruit
Gomisin J299 ↑ Mechanism is not described Human breast cancer cell lines (MCF7
and MDA-MB-231)
A component of Schisandra chinensis
fruit a Chinese herbal medicine
Lycorine168 ↑ Upregulates RIPK1 and RIPK3
expression
Multiple myeloma cell line ARH-77 Chinese medicinal herb
Matrine alkaloid166 ↑ Increases RIPK3 expression; increases
ROS production
In vitro in CCA QBC939 and Mz-ChA-1
cell lines
Component of the traditional Chinese
medical herb Sophora flavescens Ait.
Neoalbaconol201,206 ↑ Increase of RIPK1/RIPK3
colocalization, down-regulates
cIAP1/2 and TNFα receptor-
associated factors TRAFs
Nasopharyngeal carcinoma cell line
C666-1
Compound isolated from the fungus,
Albatrellus confluens
Patchouli
alcohol179
↓ Down-regulates RIPK3 and MLKL
proteins.
DSS (dextran sulfate sodium)-induced
mice colitis in vivo
Pogostemon (patchouli) leaves used in
traditional medicine
Resibufogenin162 ↑ Upregulation of RIPK3 and
phosphorylation of MLKL
In vitro MEF cells, Human CRC cell
lines (SW480, HCT-116) and SW480
cells xenografted to BALB/c-nu mice
Used as traditional Chinese medicine
component. Completed phase II of a
clinical trial on pancreatic cancer
Shikonin161,300 ↑ RIPK1 and RIPK3- dependent
necroptosis
Various human cell lines Used in traditional Chinese medicine
as a wound healing ointment
Tanshinone IIA193 ↑ Especially in the presence of caspase
inhibitors forms RIPK1/RIPK3 complex
In human hepatocellular carcinoma
HepG2 cells
Constituent of the traditional
medicinal plant Salvia miltiorrhiza
Youdujing164 ↑ Increases RIP1 expression In ectocervical Ect1/E6E7 cell line Traditional Chinese herbal formula
Wogonin192 ↓ Inhibited RIPK1 by occupying the
ATP-binding pocket
Inhibits necroptosis in cisplatin-
induced AKI mouse model
Herbal compound, was found in
Scutellaria baicalensis, ingredient of a
Japanese herbal supplement
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components, as well. The proteasome inhibitor Bortezo-
mib207 (used in Multiple Myeloma treatment) and a
HDAC inhibitor Vorinostat208 (approved for the treat-
ment of Cutaneous T cell lymphoma) have been
demonstrated to inhibit necroptosis through the upregu-
lation of necroptosis inhibitors, sequentially stabilizing
IAPs or increasing FLIP expression.
Various ROS scavengers have been implicated in the
modulation of necroptosis209,210. Dexmedetomidine (used
in moderate sedation) inhibits HMGB1 production211.
Melatonin212 (used for jetlag sleep disorder) blocks
PGAM5, while P110 is a selective inhibitor of Drp1213,
therefore, these two drugs dampen the intensity of
necroptosis via a well-documented PGAM-Drp1 pathway.
While there are no drugs on the market directly
approved to regulate necroptosis, various medicines have
the potential to both up and downregulate necroptosis,
and to interact different levels of necroptosis signaling.
Necroptosis has fundamental roles in various human
diseases which makes it rational to try and apply the
necroptosis regulator drugs in these syndromes.
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